Anti-Human Fibroblast Growth Factor 23 (Burosumab) (F540-GRP)

Fibroblast growth factor 23 (FGF23) is a hormone produced by bone cells that plays a key role in regulating phosphate levels in the body. Excessive FGF23 production leads to hypophosphatemic conditions like rickets and osteomalacia. Disorders such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) are characterized by elevated FGF23 levels, resulting in low phosphate levels and impaired bone health. Measuring FGF23 levels is critical for diagnosing these hypophosphatemic diseases and guiding treatment decisions1-3. Burosumab (KRN23) is a fully human monoclonal antibody that binds to and neutralizes excess FGF23, helping restore phosphate balance. Clinical trials have shown burosumab to be effective in treating both XLH and TIO in children and adults, improving serum phosphate levels, bone turnover, fracture healing, and reducing pain. Approved for use in these conditions, burosumab offers a targeted therapy that addresses the underlying cause of FGF23-related disorders. Ongoing studies continue to explore its long-term safety and efficacy, highlighting its potential for sustained clinical benefits2,4,5.